Genetic diversity of Vif protein in human immunodeficiency virus type 1 variants (Retroviridae: <i>Orthoretrovirinae: Lentivirus: Human immunodeficiency virus-1</i>) that circulated in the Moscow region in 2019–2020
Introduction. The Vif protein counteracts cellular deaminases, APOBEC3, which prevent viral replication. Vif is used for development of therapeutic agents. Natural polymorphisms in Vif can affect its functionality and may be associated with accelerated progression of HIV-infection to the AIDS. The s...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Central Research Institute for Epidemiology
2025-04-01
|
| Series: | Вопросы вирусологии |
| Subjects: | |
| Online Access: | https://virusjour.crie.ru/jour/article/viewFile/16744/966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. The Vif protein counteracts cellular deaminases, APOBEC3, which prevent viral replication. Vif is used for development of therapeutic agents. Natural polymorphisms in Vif can affect its functionality and may be associated with accelerated progression of HIV-infection to the AIDS. The study of Vif features in HIV-1 variants circulating in Russia has not been conducted previously.
The aim of the study: to study the genetic diversity of Vif in the HIV-1 variants that circulated in the Moscow region in 2019–2020.
Materials and methods. 234 whole blood samples obtained from HIV-infected patients without experience of therapy were analyzed. The study design included the following stages: extraction of proviral DNA, amplification of the vif gene, sequencing, identification of genetic variants, followed by a study of consensus sequences of the most common genetic variants of HIV-1, analysis of the conservation and genetic diversity of Vif-A6 (Vif protein of HIV-1 sub-subtype A6 variants) in patients with different stages of the disease, and assessment of genetic diversity of Vif-A6 in the Moscow region.
Results. A high degree of genetic diversity of vif gene was revealed. Consensus sequences of Vif in B and CRF63_02A6 variants were obtained for the first time. Characteristic substitutions in the consensus sequences were determined for the most common HIV-1 variants.
Conclusion. The limitation of this study is the small sample of B and CRF63_02A6. The results obtained may be of interest and may be taken into account in the development of therapeutic agents based on the Vif protein, as well as in the study of the pathogenicity of HIV-1 sub-subtype A6. |
|---|---|
| ISSN: | 0507-4088 2411-2097 |